These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 17693380

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS.
    J Am Coll Cardiol; 2010 Apr 27; 55(17):1780-7. PubMed ID: 20413026
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
    Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P.
    Eur Heart J; 2005 Jul 27; 26(13):1303-8. PubMed ID: 15767288
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic Peptide in patients with heart failure with versus without chronic kidney disease.
    Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R.
    Am J Cardiol; 2008 Aug 15; 102(4):469-74. PubMed ID: 18678308
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
    Nessler J, Nessler B, Kitliński M, Gackowski A, Piwowarska W, Stepniewski M.
    Kardiol Pol; 2008 Feb 15; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
    [Abstract] [Full Text] [Related]

  • 11. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy.
    Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Trawinski J, Amann-Zalan I, Hoersch S, Katus HA.
    Eur J Heart Fail; 2004 Mar 15; 6(3):343-50. PubMed ID: 14987586
    [Abstract] [Full Text] [Related]

  • 12. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
    Gundogdu F, Bozkurt E, Kiziltunc A, Sevimli S, Arslan S, Gurlertop Y, Senocak H, Karakelleoglu S.
    Echocardiography; 2007 Feb 15; 24(2):113-7. PubMed ID: 17313541
    [Abstract] [Full Text] [Related]

  • 13. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
    Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA.
    Eur Heart J; 2005 Nov 15; 26(21):2259-68. PubMed ID: 16040619
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
    Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG, Australia-New Zealand Heart Failure Group.
    J Am Coll Cardiol; 2001 Jun 01; 37(7):1781-7. PubMed ID: 11401111
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
    Poole-Wilson PA.
    Am J Cardiol; 2004 May 06; 93(9A):40B-2B. PubMed ID: 15144936
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
    Torp-Pedersen C, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lutiger B, Metra M, Remme WJ, Scherhag A, Skene A, COMET Investigators.
    Am Heart J; 2005 Feb 06; 149(2):370-6. PubMed ID: 15846279
    [Abstract] [Full Text] [Related]

  • 20. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
    Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC.
    Am Heart J; 2005 Mar 06; 149(3):541-7. PubMed ID: 15864245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.